Clinical trial
24-h Energy Expenditure and Anti-obesity Medication
Invitation only · Not applicable · 1 countries · Registry ID NCT07041983
What this study is about
This study investigates the long-term effects of anti-obesity medications (Semaglutide and Tirzepatide) on energy metabolism (24-hour energy expenditure and substrate oxidation) and body composition via Dual-energy X-ray absorptiometry (DXA)
Basic eligibility
Full registry criteria
Treatments and study arms
anti obesity medication
Patients with obesity or overweight, with at least one weight-related comorbidity who are expected to start treatment with Semaglutide (Wegovy) or Terzepatide (Mounjaro) at enrolment will be eligible to enrol into the study. Patients will be treated and observed according to normal clinical practice. Participation in this study does not limit the physicians' clinical decision making as to the most appropriate treatment for the patient during the course of the study
Primary outcomes
measurement of 24-hour energy expenditure (kilocalories) by using the metabolic chamber (whole room indirect calorimeter) at baseline and after 6 months of treatment
Study locations
1 locations were listed when this page was built. The first 40 are shown.